Eikon Therapeutics has a total of 33 patents globally, out of which 4 have been granted. Of these 33 patents, more than 58% patents are active. United States of America is where Eikon Therapeutics has filed the maximum number of patents, followed by Hong Kong (S.A.R.) and Europe (EPO). Parallelly, USA seems to be the main focused R&D centre and also is the origin country of Eikon Therapeutics.
Eikon Therapeutics founded in 2019, Eikon Therapeutics is a biopharmaceutical company developing novel treatments for life-threatening diseases through breakthrough technology at the intersection of biology, engineering, and chemistry. Its discovery platform, based on Nobel Prize-winning innovations, uses advanced microscopes to track protein movement in living cells. By enabling real-time, molecular-level insights, Eikon unlocks previously inaccessible drug targets and accelerates the discovery of life-saving therapies.
Do read about some of the most popular patents of Eikon Therapeutics which have been covered by us in this article and also you can find Eikon Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Eikon Therapeutics patent portfolio.
How many patents does Eikon Therapeutics have?
Eikon Therapeutics has a total of 33 patents globally. These patents belong to 18 unique patent families. Out of 33 patents, 19 patents are active.
How Many Patents did Eikon Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Eikon Therapeutics Applications Filed | Eikon Therapeutics Patents Granted |
| 2025 | 1 | – |
| 2024 | 14 | – |
| 2023 | 10 | – |
| 2022 | 4 | – |
| 2018 | – | 2 |
| 2016 | 1 | 1 |
| 2015 | – | 1 |
| 2014 | 1 | – |
| 2013 | 2 | – |
How many Eikon Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Eikon Therapeutics File in Different Countries?
Countries in which Eikon Therapeutics Filed Patents
| Country | Patents |
| United States of America | 5 |
| Hong Kong (S.A.R.) | 1 |
| Europe (EPO) | 1 |
| Mexico | 1 |
| Canada | 1 |
Where are Research Centres of Eikon Therapeutics Patents Located?
The Research Centre for all the Eikon Therapeutics patents is the United States of America.
Eikon Therapeutics Best Patent
US9062026B2 is the most popular patent in the Eikon Therapeutics portfolio. It has received 6 citations so far from companies like Cleave Biosciences and Turbine Simulated Cell Technologies Ltd.
What Percentage of Eikon Therapeutics US Patent Applications were Granted?
Eikon Therapeutics (Excluding its subsidiaries) has filed 5 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 4 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Eikon Therapeutics patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Eikon Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Schwegman Lundberg & Woessner P A | 4 | 100.00% |
| Jones Day | 1 | 0% |
List of Eikon Therapeutics Patents
| Eikon Therapeutics Patents | Title |
| WO2025166175A1 | Systems And Methods For Image Processing And Adaptive Control In Microscope Systems |
| WO2025129135A3 | Compositions Comprising Usp1 Inhibitors And Methods Of Using The Same |
| WO2025129076A1 | Pyridopyrimidine And Quinazoline Derivatives As Usp1 Inhibitors, Compositions Comprising Them And Methods Of Using The Same |
| WO2025128903A1 | Novel Synthesis Of Substituted Tricyclic Compounds |
| WO2025106693A1 | Methods And Compositions For Treating Cancers With High Microsatellite Instability Levels |
| WO2025064748A1 | Single Molecule Tracking Using Graph Neural Networks |
| WO2025059293A1 | Methods And Compositions For Assessing The Performance Of Instruments Adapted For Single-Molecule Tracking |
| WO2025049746A1 | Compositions Comprising Werner Syndrome Helicase Inhibitors And Methods Of Using The Same |
| WO2025042745A1 | End-Effectors For Sample-Handling Robotic Systems |
| WO2025006619A1 | Methods And Systems For Single Molecule Tracking In Cell-Free Systems |
| WO2024138093A9 | Oblique Line Scanner Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| HK40112415A | 2-Diazo-3-Oxo-2,3-Dihydrospiro[Indene-1,9′-Xanthene] Derivatives And Similar Compounds As Photoactive Fluorescent Compounds For Protein Labeling |
| EP4377311A1 | 2-Diazo-3-Oxo-2,3-Dihydrospiro[Indene-1,9′-Xanthene] Derivatives And Similar Compounds As Photoactive Fluorescent Compounds For Protein Labeling |
| WO2024168101A1 | Nucleolar Localization Using Machine-Learning-Based Inference And Segmentation |
| WO2024168110A1 | Cell Healthiness Characterization Using Machine Learning |
| WO2024138068A3 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024159100A1 | Photoactive Fluorescent Compounds And Use Thereof For Labeling Of Proteins |
| WO2024138082A1 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024137975A1 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138090A1 | Oblique Line Scanner Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138095A1 | Oblique Line Scanner Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138075A1 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138094A1 | Oblique Line Scanner Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138088A1 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| WO2024138091A1 | Systems And Methods For High Throughput Single Molecule Tracking In Living Cells |
| MX2024001109A | 2-Diazo-3-Oxo-2,3-Dihydrospiro[Indene-1,9′-Xanthene] Derivatives And Similar Compounds As Photoactive Fluorescent Compounds For Protein Labeling. |
| US20230086732A1 | Photoactive Fluorescent Compounds And Use Thereof For Labeling Of Proteins |
| WO2023009503A1 | 2-Diazo-3-Oxo-2,3-Dihydrospiro[Indene-1,9′-Xanthene] Derivatives And Similar Compounds As Photoactive Fluorescent Compounds For Protein Labeling |
| CA3226795A1 | 2-Diazo-3-Oxo-2,3-Dihydrospiro[Indene-1,9′-Xanthene] Derivatives And Similar Compounds As Photoactive Fluorescent Compounds For Protein Labeling |
| US10010554B2 | Fused Pyrimidines As Inhibitors Of P97 Complex |
| US9868722B2 | Monocyclic Pyrimidine/Pyridine Compounds As Inhibitors Of P97 Complex |
| US9475824B2 | Fused Pyrimidines As Inhibitors Of P97 Complex |
| US9062026B2 | Fused Pyrimidines And Substituted Quinazolines As Inhibitors Of P97 |
What are Eikon Therapeutics key innovation segments?
What Technologies are Covered by Eikon Therapeutics?
The chart below distributes patents filed by Eikon Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Eikon Therapeutics thinks it’s important to protect particular technological inventions.
R&D Focus: How has Eikon Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Eikon Therapeutics?
